For the Inventor, By the Inventor

Enter assignee name

Vienna, Austria

Immuno Aktiengesellschaft

USPTO Granted Patents = 83

Trademarks = 1

Forward Citations = 1,612

Loading Chart...

Loading Chart...

81 inventors (with patents filed for the assignee):

Johann J Eibl (37 out of 102 patents)

Friedrich Dorner (28 out of 91 patents)

Peter Turecek (16 out of 120 patents)

4. Yendra Linnau (15 out of 39 patents)

5. Hans Peter Schwarz (15 out of 20 patents)

6. Hans-Peter Schwarz (11 out of 107 patents)

7. Wolfgang Mundt (11 out of 63 patents)

8. Artur Mitterer (10 out of 53 patents)

9. Bernhard Fischer (8 out of 62 patents)

10. Falko-Guenter Falkner (6 out of 17 patents)

11. Anton Philapitsch (6 out of 12 patents)

12. Manfred Reiter (5 out of 71 patents)

13. Noel Barrett (5 out of 19 patents)

14. Thomas Seelich (5 out of 16 patents)

15. Ludwig Pichler (5 out of 27 patents)

Core Competencies:

Von Willebrand Factor

Recombinant Proteins

Thrombolytic Agents

Blood Coagulation Disorders

Pharmaceutical Preparations

Virus Inactivation

Immunoglobulin A

Thrombogenesis Assays

Lys-Plasminogen

Protein C

Influenza Vaccine

Tissue Adhesives

83 patents: Sort by Forward Citations

1. 6103693 - Method for isolation of highly pure von willebrand factor (2000-08-15),

2. 6103244 - Methods for generating immune responses employing modified vaccinia of (2000-08-15),

3. 6100061 - Recombinant cell clone having increased stability in serum- and (2000-08-08),

4. 6051418 - Hybrid proteins with modified activity (2000-04-18),

5. 6005077 - Use of von willebrand factor and pharmaceutical formulation (1999-12-21),

6. 5962405 - Storage-stable fibrinogen preparations (1999-10-05),

7. 5910481 - Hybrid proteins with modified activity (1999-06-08),

8. 5892005 - High molecular and low molecular fractions of von willebrand factor (1999-04-06),

9. 5883078 - Hemostyptic and tissue adhesive (1999-03-16),

10. 5880265 - Method for isolation of highly pure von willebrand factor (1999-03-09),

11. 5877152 - Method for isolation of highly pure von Willebrand Factor (1999-03-02),

12. 5872099 - High molecular and low molecular fractions of von Willebrand Factor (1999-02-16),

13. 5869617 - High and low molecular weight fractions of von Willebrand Factor and (1999-02-09),

14. 5869292 - Hybrid proteins with modified activity (1999-02-09),

15. 5866122 - Pharmaceutical preparation for treating blood coagulation disorders (1999-02-02),

Company Overview

Immuno Aktiengesellschaft, based in Vienna, Austria, specializes in the development and production of innovative therapies for blood coagulation disorders. The company focuses on key areas such as Von Willebrand Factor, recombinant proteins, and thrombolytic agents, addressing critical needs in the management of bleeding disorders. Its expertise extends to virus inactivation and the formulation of immunoglobulin A, contributing to advancements in pharmaceutical preparations and thrombogenesis assays, thereby enhancing patient care in hematology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

83 Patents

#9 in Vienna

#45 in Austria

#9,150 in the World

Vienna, Austria

Immuno Aktiengesellschaft

Forward Citations = 1,612

81 inventors:

Johann J Eibl (37 out of 102 patents)

Friedrich Dorner (28 out of 91 patents)

Peter Turecek (16 out of 120 patents)

4. Yendra Linnau (15 out of 39 patents)

5. Hans Peter Schwarz (15 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immuno Aktiengesellschaft. Retrieved from https://idiyas.com/company/immuno-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…